Filtered By:
Condition: Ischemic Stroke
Drug: Pradaxa
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 532 results found since Jan 2013.
Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device
CONCLUSION: The safety and efficacy of low-dose dabigatran and rivaroxaban were comparable to those of warfarin within 45 days after Watchman device implantation in a Chinese population.PMID:34740490 | DOI:10.1016/j.jfma.2021.10.015
Source: J Formos Med Assoc - November 6, 2021 Category: General Medicine Authors: Guohua Fu Binhao Wang Bin He Yibo Yu Zhao Wang Mingjun Feng Jing Liu Xianfeng Du Weidong Zhuo Huimin Chu Source Type: research
Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study
This study shows that NOACs may be effective and safe as secondary prevention of VTE in patients with myeloproliferative neoplasms.
Source: Journal of Cardiovascular Pharmacology - November 1, 2021 Category: Cardiology Tags: Original Article Source Type: research
Short- and long-term outcome of patients with spontaneous echo contrast or thrombus in the left atrial appendage in the era of the direct acting anticoagulants
ConclusionEven in the DOAC era, the occurrence of thrombus or SEC in the LAA is associated with a high rate of MACCE. Our study suggests that the choice of DOAC therapy may have an impact on long-term survival.Graphic abstract
Source: Clinical Research in Cardiology - November 1, 2021 Category: Cardiology Source Type: research
Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis
ConclusionsDabigatran has a favorable impact on effectiveness and safety outcomes compared with vitamin K antagonists in real-world populations.
Source: Clinical Drug Investigation - October 13, 2021 Category: Drugs & Pharmacology Source Type: research
Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study
ConclusionsAmong AF patients with a BMI>40kg/m2 or a weight>120kg in a real-world clinical setting, dabigatran was effective in reducing the risk of thromboembolism and mortality but was associated with an increased risk of bleeding when compared to warfarin. Dabigatran may be a reasonable option for AF patients with severe obesity.
Source: Journal of General Internal Medicine - September 20, 2021 Category: Internal Medicine Source Type: research
Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data
This study suggested that in the current use of DOACs in Japanese patients with NVAF, dabigatran had a significantly lower risk of major bleeding than apixaban, but there was no significant difference in effectiveness among the four DOACs.PMID:34471057 | DOI:10.1248/bpb.b21-00230
Source: Biological and Pharmaceutical Bulletin - September 2, 2021 Category: Drugs & Pharmacology Authors: Aya Enomoto Yasunari Mano Yohei Kawano Tomoki Nishikawa Takao Aoyama Yoshiyuki Sasaki Masashi Nagata Hiromitsu Takahashi Source Type: research
